# SLC7A2

## Overview
The SLC7A2 gene encodes the protein solute carrier family 7 member 2, which functions as a cationic amino acid transporter. This protein is integral to the transport of essential amino acids such as arginine, lysine, and ornithine across cell membranes, playing a critical role in numerous physiological processes, including nitric oxide synthesis, immune response, and cellular growth (Visigalli2010Regulation). As a transmembrane transporter, SLC7A2 is involved in the regulation of vascular function and glucose homeostasis, with significant expression in endothelial and pancreatic islet α cells (Spears2023Pancreatic). The gene's expression is modulated by various signaling pathways and environmental stimuli, influencing its role in muscle differentiation and cancer cell behavior (Jiang2023Lower; Huang2023Integrated). Alterations in SLC7A2 expression have been linked to several pathological conditions, including cancer, neurodegenerative disorders, and metabolic diseases, underscoring its potential as a therapeutic target (Gaudet2024Elevated; Xia2021SLC7A2).

## Function
The SLC7A2 gene encodes a cationic amino acid transporter that is primarily responsible for the uptake of arginine, lysine, and ornithine into cells. This transporter is crucial for various cellular and physiological processes, including nitric oxide synthesis, immune response, and cellular growth. In endothelial cells, SLC7A2 is involved in the regulation of arginine transport, which is essential for nitric oxide production, a key factor in vasodilation and blood pressure regulation (Visigalli2010Regulation). The gene is expressed in pancreatic islet α cells, where it plays a significant role in arginine-stimulated glucagon and insulin secretion, impacting glucose homeostasis and hormone regulation (Spears2023Pancreatic).

SLC7A2 is also implicated in myoblast differentiation and muscle fiber formation, with its expression increasing during muscle differentiation and aging. This suggests a role in maintaining muscle health and function, potentially influencing conditions like sarcopenia (Huang2023Integrated). The gene's activity is regulated by various factors, including protein kinase C activation and inflammatory stimuli, which modulate its expression and function in different tissues (Sala2002Twoway; Visigalli2010Regulation).

## Clinical Significance
Alterations in the expression of the SLC7A2 gene have been implicated in several diseases, particularly cancers and neurodegenerative disorders. In non-small cell lung cancer (NSCLC), lower expression of SLC7A2 is associated with enhanced multidrug resistance, reduced immune cell infiltration, and worse prognosis. This gene's downregulation in NSCLC cells leads to increased cell proliferation and decreased sensitivity to chemotherapeutic drugs like paclitaxel and cisplatin (Jiang2023Lower). In hepatocellular carcinoma (HCC), SLC7A2 deficiency is linked to poor prognosis due to increased recruitment of myeloid-derived suppressor cells (MDSCs), which promote tumor progression by suppressing immune responses (Xia2021SLC7A2).

In Huntington's disease (HD), SLC7A2 is upregulated, contributing to an abnormal neuroinflammatory response and increased nitrosative stress. This upregulation is associated with heightened production of nitric oxide, leading to protein nitrosylation and mitochondrial fragmentation, which are implicated in HD pathogenesis (Gaudet2024Elevated). Additionally, mutations in SLC7A2 can lead to metabolic disorders, as seen in a case of a newborn with high blood arginine levels due to loss-of-function mutations, which required dietary management to normalize amino acid levels (Yahyaoui2019Amino). These findings highlight the clinical significance of SLC7A2 in various diseases, suggesting its potential as a therapeutic target.

## Interactions
SLC7A2, a member of the solute carrier family, is involved in the transport of cationic amino acids and participates in various protein interactions that influence cellular processes. In non-small cell lung cancer (NSCLC), SLC7A2 interacts with the transcription factor E2F1, which may play a role in modulating cancer cell behavior and drug resistance (Jiang2023Lower). This interaction suggests a potential mechanism by which SLC7A2 influences cellular proliferation and chemoresistance.

In endothelial cells, SLC7A2 is regulated by protein kinase C alpha (PKCα), which stimulates the expression of CAT2 transporters encoded by SLC7A2. This regulation involves the activation of the MEK/ERK1/2 signaling cascade and the transcription factor AP-1, leading to increased arginine transport and altered nitric oxide production (Visigalli2010Regulation). The interaction with PKCα highlights the role of SLC7A2 in endothelial function and arginine metabolism.

In hepatocellular carcinoma (HCC), SLC7A2 deficiency is associated with enhanced recruitment of myeloid-derived suppressor cells (MDSCs) through the upregulation of CXCL1 expression via the PI3K/Akt/NF-κB pathway. This interaction influences tumor progression and immune cell dynamics in the tumor microenvironment (Xia2021SLC7A2).


## References


1. (Spears2023Pancreatic) Pancreatic islet α cell function and proliferation requires the arginine transporter SLC7A2. This article has 1 citations.

[2. (Visigalli2010Regulation) Rossana Visigalli, Amelia Barilli, Alessandro Parolari, Roberto Sala, Bianca Maria Rotoli, Ovidio Bussolati, Gian C. Gazzola, and Valeria Dall’Asta. Regulation of arginine transport and metabolism by protein kinase cα in endothelial cells: stimulation of cat2 transporters and arginase activity. Journal of Molecular and Cellular Cardiology, 49(2):260–270, August 2010. URL: http://dx.doi.org/10.1016/j.yjmcc.2010.04.007, doi:10.1016/j.yjmcc.2010.04.007. This article has 19 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/j.yjmcc.2010.04.007)

[3. (Huang2023Integrated) Tiane Huang, Jing Zhou, Benhui Wang, Xiang Wang, Wanli Xiao, Mengqi Yang, Yan Liu, Qiquan Wang, Yang Xiang, and Xinqiang Lan. Integrated amino acids and transcriptome analysis reveals arginine transporter slc7a2 is a novel regulator of myogenic differentiation. International Journal of Molecular Sciences, 25(1):95, December 2023. URL: http://dx.doi.org/10.3390/ijms25010095, doi:10.3390/ijms25010095. This article has 1 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/ijms25010095)

[4. (Gaudet2024Elevated) Ian D. Gaudet, Hongyuan Xu, Emily Gordon, Gianna A. Cannestro, Michael L. Lu, and Jianning Wei. Elevated slc7a2 expression is associated with an abnormal neuroinflammatory response and nitrosative stress in huntington’s disease. Journal of Neuroinflammation, February 2024. URL: http://dx.doi.org/10.1186/s12974-024-03038-2, doi:10.1186/s12974-024-03038-2. This article has 2 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s12974-024-03038-2)

[5. (Xia2021SLC7A2) Suhong Xia, Jingwen Wu, Wangdong Zhou, Mingyu Zhang, Kai Zhao, Jingmei Liu, Dean Tian, and Jiazhi Liao. Slc7a2 deficiency promotes hepatocellular carcinoma progression by enhancing recruitment of myeloid-derived suppressors cells. Cell Death &amp; Disease, June 2021. URL: http://dx.doi.org/10.1038/s41419-021-03853-y, doi:10.1038/s41419-021-03853-y. This article has 23 citations.](https://doi.org/10.1038/s41419-021-03853-y)

[6. (Sala2002Twoway) Roberto Sala, Bianca Maria Rotoli, Emanuela Colla, Rossana Visigalli, Alessandro Parolari, Ovidio Bussolati, Gian C. Gazzola, and Valeria Dall’Asta. Two-way arginine transport in human endothelial cells: tnf-α stimulation is restricted to system y+. American Journal of Physiology-Cell Physiology, 282(1):C134–C143, January 2002. URL: http://dx.doi.org/10.1152/ajpcell.2002.282.1.c134, doi:10.1152/ajpcell.2002.282.1.c134. This article has 49 citations.](https://doi.org/10.1152/ajpcell.2002.282.1.c134)

[7. (Jiang2023Lower) Shanshan Jiang, Junrong Zou, Jianyu Dong, Huimian Shi, Jie Chen, Yan Li, Xianglong Duan, and Wensheng Li. Lower slc7a2 expression is associated with enhanced multidrug resistance, less immune infiltrates and worse prognosis of nsclc. Cell Communication and Signaling, January 2023. URL: http://dx.doi.org/10.1186/s12964-022-01023-x, doi:10.1186/s12964-022-01023-x. This article has 7 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s12964-022-01023-x)

[8. (Yahyaoui2019Amino) Raquel Yahyaoui and Javier Pérez-Frías. Amino acid transport defects in human inherited metabolic disorders. International Journal of Molecular Sciences, 21(1):119, December 2019. URL: http://dx.doi.org/10.3390/ijms21010119, doi:10.3390/ijms21010119. This article has 41 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/ijms21010119)